Fintel reports that on July 21, 2025, Truist Securities initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy recommendation. Analyst Price Forecast Suggests 6.19% Upside As of July ...

More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...

Under Target's current policy, the company will match the price of store-bought products if customers "then find the ...

Reuters is tracking how companies are responding to the threat posed by <a href=" target="_blank" rel="noopener noreferrer ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

A high-level overview of Regeneron Pharmaceuticals, Inc. (REGN) stock. View (REGN) real-time stock price, chart, news, analysis, analyst reviews and more.

Bailard Inc. drastically reduced its stake in Regeneron Pharmaceuticals, offloading 69.9% of its shares in the first quarter.

Target CEO Brian Cornell said in an earnings call in May that U.S. tariffs were one factor in a number of “massive potential ...

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. Yet another ...

CWM LLC has more than doubled its stake in Regeneron Pharmaceuticals, snapping up an additional 2,007 shares to now hold a ...